Establishing the prevalence of common tissue-specific autoantibodies following severe acute respiratory syndrome coronavirus 2 infection,Clinical & Experimental Immunology

当前位置： X-MOL 学术 › Clin. Exp. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Establishing the prevalence of common tissue-specific autoantibodies following severe acute respiratory syndrome coronavirus 2 infection
Clinical & Experimental Immunology ( IF 3.4 ) Pub Date : 2021-06-03 , DOI: 10.1111/cei.13623
Alex G Richter ₁ , Adrian M Shields ₁ , Abid Karim ₁ , David Birch ₁ , Sian E Faustini ₁ , Lora Steadman ₂ , Kerensa Ward ₁ , Timothy Plant ₁ , Gary Reynolds ₂ , Tonny Veenith ₃ , Adam F Cunningham ₂ , Mark T Drayson ₁ , David C Wraith ₂

Affiliation

Coronavirus 19 (COVID-19) has been associated with both transient and persistent systemic symptoms that do not appear to be a direct consequence of viral infection. The generation of autoantibodies has been proposed as a mechanism to explain these symptoms. To understand the prevalence of autoantibodies associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, we investigated the frequency and specificity of clinically relevant autoantibodies in 84 individuals previously infected with SARS-CoV-2, suffering from COVID-19 of varying severity in both the acute and convalescent setting. These were compared with results from 32 individuals who were on the intensive therapy unit (ITU) for non-COVID reasons. We demonstrate a higher frequency of autoantibodies in the COVID-19 ITU group compared with non-COVID-19 ITU disease control patients and that autoantibodies were also found in the serum 3–5 months post-COVID-19 infection. Non-COVID patients displayed a diverse pattern of autoantibodies; in contrast, the COVID-19 groups had a more restricted panel of autoantibodies including skin, skeletal muscle and cardiac antibodies. Our results demonstrate that respiratory viral infection with SARS-CoV-2 is associated with the detection of a limited profile of tissue-specific autoantibodies, detectable using routine clinical immunology assays. Further studies are required to determine whether these autoantibodies are specific to SARS-CoV-2 or a phenomenon arising from severe viral infections and to determine the clinical significance of these autoantibodies.

中文翻译：

确定严重急性呼吸综合征冠状病毒 2 感染后常见组织特异性自身抗体的流行率

冠状病毒 19 (COVID-19) 与短暂和持续的全身症状有关，这些症状似乎不是病毒感染的直接后果。自身抗体的产生已被提议作为解释这些症状的机制。为了了解与严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 感染相关的自身抗体的流行情况，我们调查了 84 名既往感染过 SARS-CoV-2、患有 COVID-19 的个体中临床相关自身抗体的频率和特异性。在急性和恢复期都有不同的严重程度。这些结果与 32 名因非新冠原因而入住强化治疗室 (ITU) 的患者的结果进行了比较。我们证明，与非 COVID-19 ITU 疾病控制患者相比，COVID-19 ITU 组中自身抗体出现的频率更高，并且在 COVID-19 感染后 3-5 个月的血清中也发现了自身抗体。非新冠肺炎患者表现出多种自身抗体模式；相比之下，COVID-19 组的自身抗体范围更有限，包括皮肤、骨骼肌和心脏抗体。我们的结果表明，SARS-CoV-2 呼吸道病毒感染与有限的组织特异性自身抗体的检测有关，可以使用常规临床免疫学检测来检测。需要进一步的研究来确定这些自身抗体是否针对 SARS-CoV-2 或严重病毒感染引起的现象，并确定这些自身抗体的临床意义。

更新日期：2021-07-12

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文